Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Chills

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    137 result(s) found for: Chills. Displaying page 1 of 7.
    1  2  3  4  5  6  7  Next»
    EudraCT Number: 2010-021571-88 Sponsor Protocol Number: 920‘135 Start Date*: 2011-11-16
    Sponsor Name:Bioforce AG Roggwil TG
    Full Title: Echinaforce Hotdrink versus Oseltamivir in the Treatment of acute uncomplicated Flu
    Medical condition: acute uncomplicated influenza
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2024-000001-33 Sponsor Protocol Number: C4591048 Start Date*: 2024-02-07
    Sponsor Name:BioNTech SE
    Full Title: A Master Phase 1/2/3 Protocol to Investigate the Safety, Tolerability, and Immunogenicity of Variant-Adapted BNT162b2 RNA-Based Vaccine Candidate(s) in Healthy Children
    Medical condition: Protection against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2)
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    23.0 10021881 - Infections and infestations 10084510 Coronavirus infections HLT
    23.1 10021881 - Infections and infestations 10084529 2019 novel coronavirus infection LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2020-000755-13 Sponsor Protocol Number: DACLEAN Start Date*: 2020-03-31
    Sponsor Name:CHU de Poitiers
    Full Title: ESTIMATION OF THE INCIDENCE OF COLONIZATION OF PERIPHERAL VENOUS CATHETERS AFTER SKIN DISINFECTION WITH 0.5% SODIUM HYPOCHLORITE, PRECEDED OR NOT BY AN APPLICATION OF 70% ETHANOL: PILOT, MONOCENTRI...
    Medical condition: Bacterial colonization of peripheral venous catheters
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10069718 Bacterial colonization LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-004072-19 Sponsor Protocol Number: Acti-INSP-001 Start Date*: 2012-12-28
    Sponsor Name:Vectura GmbH
    Full Title: A randomized, double-blind, parallel group, placebo controlled Phase II study to evaluate the safety and efficacy of inhaled LASAG and Placebo, applied three times daily in adult hospitalized patie...
    Medical condition: Influenza A and B
    Disease: Version SOC Term Classification Code Term Level
    17.0 10021881 - Infections and infestations 10022000 Influenza PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) CZ (Prematurely Ended) HU (Prematurely Ended) SK (Prematurely Ended) ES (Prematurely Ended) LV (Prematurely Ended) LT (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-001235-31 Sponsor Protocol Number: DEALSZ-2019-001 Start Date*: 2019-11-26
    Sponsor Name:Charité – Universitätsmedizin Berlin
    Full Title: Factor XII-associated cold autoinflammatory syndrome (FACAS) linked to kallikrein-kinin pathology: Proof of concept treatment with Lanadelumab (DX-2930)
    Medical condition: Lanadelumab in patients with Factor XII-associated cold autoinflammatory syndrome (FACAS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10072220 Autoinflammatory disease PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-002688-32 Sponsor Protocol Number: 1602T0832 Start Date*: 2017-11-07
    Sponsor Name:Shionogi Ltd.
    Full Title: A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared with Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Patients with Influenza at High Risk of Infl...
    Medical condition: Influenza
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10022005 Influenza viral infections HLT
    20.1 100000004862 10022002 Influenza A virus infection LLT
    20.1 100000004862 10022003 Influenza B virus infection LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) LV (Completed) HU (Completed) GB (Completed) PL (Completed) BG (Completed) ES (Completed) BE (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2013-001869-16 Sponsor Protocol Number: BRN-C-2013-02 Start Date*: 2013-09-24
    Sponsor Name:Boiron Laboratoires
    Full Title: A randomised, multi-centre, parallel group, double-blind, placebo-controlled study to assess the efficacy and safety of Oscillococcinum® in the treatment of symptoms of Influenza-like illness (ILI)
    Medical condition: Systemic and respiratory symptoms of Influenza-like-illness (ILI)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004867 10016797 Flu-like symptoms LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-005588-29 Sponsor Protocol Number: 1487-0001 Start Date*: 2021-05-12
    Sponsor Name:SCS Boehringer Ingelheim Comm. V
    Full Title: A Phase II/III seamless, randomised, double-blind, placebo-controlled, parallel-group, group-sequential study to evaluate efficacy, safety and tolerability of BI 767551 for the treatment of sympt...
    Medical condition: COVID-19
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10084268 COVID-19 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) DK (Completed) NL (Prematurely Ended) PT (Completed) DE (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-002641-42 Sponsor Protocol Number: C4591001 Start Date*: 2020-09-04
    Sponsor Name:BioNTech SE
    Full Title: A PHASE 1/2/3, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND, DOSE-FINDING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, IMMUNOGENICITY, AND EFFICACY OF SARS-COV-2 RNA VACCINE CANDIDATES AGAINST COV...
    Medical condition: Protection against COVID-19
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-003372-73 Sponsor Protocol Number: ZTI-01-200 Start Date*: 2016-04-11
    Sponsor Name:Zavante Therapeutics, Inc.
    Full Title: A Multi-center, Randomized, Double-blind, Comparative Study to Evaluate the Safety and Efficacy of ZTI-01 Versus Piperacillin/Tazobactam in the Treatment of Complicated Urinary Tract Infections, In...
    Medical condition: Complicated Urinary Tract Infections, Including Acute Pyelonephritis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10021881 - Infections and infestations 10037597 Pyelonephritis acute PT
    19.0 10021881 - Infections and infestations 10046577 Urinary tract infections HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Completed) LT (Completed) LV (Completed) SK (Completed) PL (Completed) EE (Completed) GR (Completed) BG (Completed) RO (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2012-000712-29 Sponsor Protocol Number: BV2012/05 Start Date*: 2012-09-03
    Sponsor Name:OM Pharma SA
    Full Title: Clinical and immune modifying capacity of Broncho-Vaxom® tested by LPS challenge in healthy volunteers A randomized double-blind placebo-controlled trial
    Medical condition: healthy volunteers intended indication : Experimental induced bronchitis in healthy volunteers
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10021832 Infection induced LLT
    14.1 10021881 - Infections and infestations 10006451 Bronchitis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-001402-38 Sponsor Protocol Number: CTU/2020/352 Start Date*: 2020-10-20
    Sponsor Name:University College London
    Full Title: An international, Bayesian platform adaptive, randomized, placebo-controlled trial assessing the effectiveness of candidate interventions in preventing COVID-19 disease in healthcare workers.
    Medical condition: Coronavirus disease 2019 (COVID-19), also known as SARS-CoV-2 infection
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10084268 COVID-19 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2020-002733-15 Sponsor Protocol Number: ACT-CS-006 Start Date*: 2020-10-14
    Sponsor Name:ACTICOR BIOTECH
    Full Title: A RANDOMIZED, DOUBLE BLIND, MULTICENTER, PLACEBO CONTROLLED, PARALLEL GROUP, EXPLORATORY EFFICACY AND SAFETY STUDY OF GLENZOCIMAB IN SARS-Cov-2-RELATED ACUTE RESPIRATORY DISTRESS SYNDROME
    Medical condition: Respiratory Distress Syndrome Related to SARS-Cov-2
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-004038-12 Sponsor Protocol Number: 19-01 Start Date*: 2021-12-10
    Sponsor Name:CENTRE HOSPITALIER ANNECY GENEVOIS
    Full Title: Randomized open-label controlled trial evaluating a single-dose intravenous Dalbavancin versus standard antibiotic therapy during catheter-related bloodstream infections due to Staphylococcus aureus
    Medical condition: Staphylococcus aureus catheter bloodstream infection
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-003280-22 Sponsor Protocol Number: AI452-032 Start Date*: 2013-08-13
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: Phase 3 open label study evaluating the efficacy and safety of pegylated interferon lambda-1a, in combination with ribavirin and daclatasvir, for treatment of chronic HCV infection with treatment n...
    Medical condition: Chronic Hepatitis C Virus (HCV) Infection (Genotypes 1, 2, 3, 4)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10008912 Chronic hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) IT (Completed) DE (Completed) ES (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2018-003671-35 Sponsor Protocol Number: SPR994-301 Start Date*: 2019-04-18
    Sponsor Name:Spero Therapeutics, Inc.
    Full Title: A Phase 3, Randomized, Double-blind, Double-dummy, Multicenter, Prospective Study to Assess the Efficacy, Safety and Pharmacokinetics of Orally Administered Tebipenem Pivoxil Hydrobromide (SPR994) ...
    Medical condition: complicated urinary tract infection or acute pyelonephritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10046571 Urinary tract infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) LV (Completed) BG (Completed) HU (Completed) PL (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2021-003458-22 Sponsor Protocol Number: BNT162-17 Start Date*: 2021-10-04
    Sponsor Name:BioNTech SE
    Full Title: A Phase II trial to evaluate the safety and immunogenicity of SARS-CoV-2 monovalent and multivalent RNA-based vaccines in healthy subjects
    Medical condition: Protection against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2).
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    23.0 10021881 - Infections and infestations 10084510 Coronavirus infections HLT
    23.1 10021881 - Infections and infestations 10084529 2019 novel coronavirus infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-021874-12 Sponsor Protocol Number: H01_04TP Start Date*: 2010-09-13
    Sponsor Name:Novartis Vaccines Institute for Global Health (NVGH)
    Full Title: A Phase 2, Randomized, Observer–blind, Controlled, Single Center Study to Evaluate the Safety and Immunogenicity of Three Formulations of the NVGH Glycoconjugate Vaccine against S. Typhi in Adult S...
    Medical condition: Salmonella enterica serovar Typhi (S. Typhi) disease
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2020-001903-17 Sponsor Protocol Number: HMos-012020 Start Date*: 2020-06-10
    Sponsor Name:HOSPITAL UNIVERISTARIO DE MOSTOLES
    Full Title: A randomized clinical trial (IIIb) of eficacy of a single dose of Tocilizumab or a combination of Tocilizumab plus Vitamin D (single i.m. dose) for the treatment of the COVID-19 hyperimmune complic...
    Medical condition: COVID INFECTION IS A MILD FLU LIKE CONDITION WITH MILD FEVER, DRY COUGH, WIDESPREAD TENDERNESS AND OLFACTORY DISFUNCTION FOLLOWED BY A SERIOUS SITUATION IN SOME 20% OF PATIENTS WITH OVERT FEVER, MA...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-001404-20 Sponsor Protocol Number: V58P1S Start Date*: 2007-05-14
    Sponsor Name:Novartis Vaccines and Diagnostics GmbH & Co. KG
    Full Title: A Phase III, multicenter, uncontrolled, open-label study to evaluate safety and immunogenicity of a single intramuscular dose of a trivalent subunit influenza vaccine produced in mammalian cell cul...
    Medical condition: No medical condition; healthy volunteers will be recruited into clinical trial for annual approval of Influenza vaccine with new strain composition according to WHO and EMEA recommendation and CPMP...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Jul 10 03:52:42 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA